<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; pharmaceutical</title>
	<atom:link href="http://www.tapanray.in/tag/pharmaceutical/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Thu, 21 May 2026 07:11:08 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Drug Data Exclusivity in India: Innovation Catalyst or Affordability Risk for Indian Pharma?</title>
		<link>http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma</link>
		<comments>http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/#comments</comments>
		<pubDate>Sat, 06 Dec 2025 14:33:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[life-saving]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Ministry of Commerce]]></category>
		<category><![CDATA[ministry of health]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11008</guid>
		<description><![CDATA[For over four decades, India’s pharmaceutical industry has been built on a powerful moral and economic proposition: that life-saving medicines should be affordable, accessible, and globally available from Indian manufacturing prowess. This principle transformed India into the “pharmacy of the developing &#8230; <a href="http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>In the Age of AI, Why Emotional Intelligence Is the New Competitive Edge in Indian Pharma Marketing</title>
		<link>http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing</link>
		<comments>http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/#comments</comments>
		<pubDate>Sun, 16 Nov 2025 06:32:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advantage]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[competitive]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[edge]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[empathy]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11000</guid>
		<description><![CDATA[In today’s AI-driven world — where scientific excellence, product claims, and competitive pricing are no longer enough to differentiate pharmaceutical companies — Emotional Intelligence (EI) is rapidly emerging as the new strategic advantage in Indian pharma marketing. As doctors face shrinking time, patients demand &#8230; <a href="http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Beyond the Business Card: What Retirement Truly Gives Back</title>
		<link>http://www.tapanray.in/beyond-the-business-card-what-retirement-truly-gives-back/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=beyond-the-business-card-what-retirement-truly-gives-back</link>
		<comments>http://www.tapanray.in/beyond-the-business-card-what-retirement-truly-gives-back/#comments</comments>
		<pubDate>Sun, 26 Oct 2025 07:30:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Card]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[p0wer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[retirement]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10986</guid>
		<description><![CDATA[A thought-provoking LinkedIn post by a highly accomplished veteran of the pharmaceutical industry — long retired, but still as insightful as ever — recently caught my attention. It sparked a series of reflections on an issue that deeply resonates with &#8230; <a href="http://www.tapanray.in/beyond-the-business-card-what-retirement-truly-gives-back/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/beyond-the-business-card-what-retirement-truly-gives-back/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>From Share-of-Voice to Share-of-Outcomes: How Indian Pharma Is Rewriting Marketing</title>
		<link>http://www.tapanray.in/from-share-of-voice-to-share-of-outcomes-how-indian-pharma-is-rewriting-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=from-share-of-voice-to-share-of-outcomes-how-indian-pharma-is-rewriting-marketing</link>
		<comments>http://www.tapanray.in/from-share-of-voice-to-share-of-outcomes-how-indian-pharma-is-rewriting-marketing/#comments</comments>
		<pubDate>Sun, 07 Sep 2025 07:39:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rewriting]]></category>
		<category><![CDATA[share of outcomes]]></category>
		<category><![CDATA[share of voice]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10967</guid>
		<description><![CDATA[If you zoom out on India’s pharma market over the past 18 months, one pattern jumps off the page: marketing is no longer just about pushing brands; it’s about owning moments across the care journey - from the first symptom search to &#8230; <a href="http://www.tapanray.in/from-share-of-voice-to-share-of-outcomes-how-indian-pharma-is-rewriting-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/from-share-of-voice-to-share-of-outcomes-how-indian-pharma-is-rewriting-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Indian Pharma Marketing’s AI Moment: Lead the Change or Fall Behind</title>
		<link>http://www.tapanray.in/indian-pharma-marketings-ai-moment-lead-the-change-or-fall-behind/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-pharma-marketings-ai-moment-lead-the-change-or-fall-behind</link>
		<comments>http://www.tapanray.in/indian-pharma-marketings-ai-moment-lead-the-change-or-fall-behind/#comments</comments>
		<pubDate>Fri, 23 May 2025 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[adoption]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[behind]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Checklist]]></category>
		<category><![CDATA[fall]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[identities]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[Lead]]></category>
		<category><![CDATA[leaders]]></category>
		<category><![CDATA[lifeline]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[moment]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[ROI]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10899</guid>
		<description><![CDATA[(With An Actionable AI Adoption Checklist below for Indian Pharma Marketers) India’s pharmaceutical market is one of the most complex and exciting in the world. With over 60,000 brands battling for attention, millions of patients, and a healthcare landscape rapidly evolving, &#8230; <a href="http://www.tapanray.in/indian-pharma-marketings-ai-moment-lead-the-change-or-fall-behind/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-pharma-marketings-ai-moment-lead-the-change-or-fall-behind/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Revolutionizing Indian Pharma: The Rise of AI and Its Transformative Impact</title>
		<link>http://www.tapanray.in/revolutionizing-indian-pharma-the-rise-of-ai-and-its-transformative-impact/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=revolutionizing-indian-pharma-the-rise-of-ai-and-its-transformative-impact</link>
		<comments>http://www.tapanray.in/revolutionizing-indian-pharma-the-rise-of-ai-and-its-transformative-impact/#comments</comments>
		<pubDate>Thu, 13 Mar 2025 11:12:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Game-changing]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revolutionizing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10883</guid>
		<description><![CDATA[I find it fascinating that some well-established consulting firms like E&#38;Y have recently published multiple reports on AI in the pharmaceutical industry. These reports, often released alongside industry events or as part of broader research initiatives, provide valuable insights rather than a &#8230; <a href="http://www.tapanray.in/revolutionizing-indian-pharma-the-rise-of-ai-and-its-transformative-impact/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/revolutionizing-indian-pharma-the-rise-of-ai-and-its-transformative-impact/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Indian Drug Industry’s Looming Talent Crisis &#8211; A Recent Landscape</title>
		<link>http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape</link>
		<comments>http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/#comments</comments>
		<pubDate>Thu, 18 Jul 2024 07:41:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[academia]]></category>
		<category><![CDATA[Academic]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[Diversity]]></category>
		<category><![CDATA[great]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[inclusion]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[looming]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[re-skilling]]></category>
		<category><![CDATA[resignation]]></category>
		<category><![CDATA[shortage]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[talent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[up-skilling]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10869</guid>
		<description><![CDATA[India&#8217;s pharmaceutical industry, a global generics and drug manufacturing powerhouse, is facing a critical talent deficit. The shortage of skilled professionals is impeding innovation, drug development, and the industry&#8217;s overall competitiveness. This challenge, exacerbated by recent industry dynamics, demands immediate &#8230; <a href="http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>UCPMP 2024: Game Changer or False Dawn?</title>
		<link>http://www.tapanray.in/ucpmp-2024-game-changer-or-false-dawn/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ucpmp-2024-game-changer-or-false-dawn</link>
		<comments>http://www.tapanray.in/ucpmp-2024-game-changer-or-false-dawn/#comments</comments>
		<pubDate>Tue, 19 Mar 2024 08:10:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Changer]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[dawn]]></category>
		<category><![CDATA[false]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP 2024]]></category>
		<category><![CDATA[Uniform]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10859</guid>
		<description><![CDATA[On March 12, 2024, the Department of Pharmaceuticals (DoP) of the Government of India notified the new Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024. Having gone through the details, many construe that aiming to finally clean up pharmaceutical marketing practices &#8230; <a href="http://www.tapanray.in/ucpmp-2024-game-changer-or-false-dawn/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ucpmp-2024-game-changer-or-false-dawn/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Criticality of Bridging the Skill Gap in Today’s Indian Pharma Industry</title>
		<link>http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry</link>
		<comments>http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/#comments</comments>
		<pubDate>Sun, 17 Sep 2023 07:14:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[increase]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PMKVY.40.]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[shortage]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[skilled]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[training]]></category>
		<category><![CDATA[workers]]></category>
		<category><![CDATA[workforce]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10820</guid>
		<description><![CDATA[To address the shortage of adequately skilled workers in the country, in 2023, the Government of India released a new version of the national skill development initiative called Pradhan Mantri Kaushal Vikas Yojana 4.0 (PMKVY 4.0). It is touted as a &#8230; <a href="http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Prescription In Generic Names Only, No Branded Generics</title>
		<link>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-prescription-in-generic-names-only-no-branded-generics</link>
		<comments>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/#comments</comments>
		<pubDate>Sun, 20 Aug 2023 07:24:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[accountability.]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[branded generics]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[IMA]]></category>
		<category><![CDATA[increased]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[influence]]></category>
		<category><![CDATA[lack]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[names]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[rationale]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transparency]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10812</guid>
		<description><![CDATA[The World Bank Report released on April 07, 2023 highlights that patients&#8217; Out-of-Pocket (OoP) expenses as a percentage of their total healthcare expenditure in India still accounted for as high as 50.59%. This means that patients in India generally pay for the &#8230; <a href="http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
